Esperion Therapeutics (NASDAQ:ESPR), Analyst Ratings, Price Targets, Predictions

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Goldman Sachs on May 24, 2022. The analyst firm set a price target for $3.00 expecting ESPR to fall to within 12 months (a possible -52.31% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Goldman Sachs, and Esperion Therapeutics maintained their sell rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on May 24, 2022 so you should expect the next rating to be made available sometime around May 24, 2023.

While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a maintained with a price target of $3.50 to $3.00. The current price Esperion Therapeutics (ESPR) is trading at is $6.29, which is out of the analyst’s predicted range.